Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease

Ulcerative Colitis Clinical Trial

Official title:

Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Subjects With Inflammatory Bowel Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03546868
• Other study ID #: FSPG -1701
• Status: Completed
• Phase: Phase 2
• Start date: August 14, 2018
• Est. completion date: January 11, 2019

Study information

• Verified date: December 2020
• Source: Asan Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diagnostic validity of [18F]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Description:

[18F]FSPG PET/CT imaging will noninvasively assess system xc- of cancer and inflammation. Diagnostic validity of [18F]FSPG for assessing disease activity will be assessed in subjects with inflammatory bowel disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 11, 2019
• Est. primary completion date: January 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 79 Years

Eligibility

Inclusion Criteria:

• Subject is aged between 19 and 79 years and male or female of any race/ethnicity.
• Subject has had ulcerative colitis or Crohn's disease diagnosed by clinical, endoscopic and histologic evidence at least 3 months prior to screening.
• Subject has symptoms suggestive of active disease at the time of enrollment.
• Subject is scheduled to undergo sigmoidoscopy or colonoscopy for ulcerative colitis or Crohn's disease within 7 days prior to or after the planned study with [18F]FSPG administration.

Exclusion Criteria:

• Subject or subject's legally acceptable representative does not provide written informed consent.
• Subject displays clinical signs of ischemic colitis or has an evidence of pathogenic bowel infection.
• Subject is diagnosed as having inflammatory bowel disease unclassified.
• Subject has been treated with sulfasalazine or intravenous corticosteroids within the previous four weeks prior to the planned study with [18F]FSPG administration.
• Dose escalation of the current inflammatory bowel disease drugs or starting a new oral aminosalicylate, corticosteroid, immunomodulator, biologics, antibiotics, probiotics, or topical preparations is scheduled from the study enrollment to the scheduled sigmoidoscopy or colonoscopy, or 24 hours after [18F]FSPG administration . The dose escalation or starting a new antidiarrheal and/or analgesic drug is allowed.
• Female subject is pregnant or nursing. Exclusion of the possibility of pregnancy is made by one of the following: 1) Woman is physiologically post-menopausal (cessation of menses for more than 2 years), 2) woman is surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy, or 3) if the woman is of childbearing potential, a serum or urine pregnancy test performed within 24 hours immediately prior to administration of [18F]FSPG has to be negative and the women is advised to apply contraceptive measures during her participation in this study.
• Subject has concurrent severe and/or uncontrolled and/or unstable medical disease (e.g. congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic renal or hepatic disease which could compromise participation in the study) in the judgment of the investigator.
• Subject is a relative of the investigator, student of the investigator or otherwise dependent.
• Subject has received any investigational drugs or devices within four weeks prior to the study enrollment.
• Subject has been previously included in this study.
• Subject has any other condition or personal circumstances that, in the judgment of the investigator, might make collection of complete data difficult or impossible.
• Subject is allergic to hyoscine or any of ingredients of hyoscine butylbromide, or has myasthenia gravis, megacolon, closed angle glaucoma, or obstructive prostatic hypertrophy.

Related Conditions & MeSH terms

• Colitis, Ulcerative
• Crohn Disease
• Inflammatory Bowel Diseases
• Intestinal Diseases
• Ulcerative Colitis

Intervention

Drug:
• [18F]FSPG
Patients will receive 200 MBq of [18F]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease

Locations

Country	Name	City	State
Korea, Republic of	Asan Foundation	Seoul	Songpa-gu
Korea, Republic of	Asan Foundation	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Asan Foundation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity of active disease	Sensitivity and specificity of [18F]FSPG PET/CT for the diagnosis of subjects with endoscopic evidence of active disease	60 - 75 min
Primary	Sensitivity and specificity of severe disease (presence of ulceration)	Sensitivity and specificity of [18F]FSPG PET/CT for the diagnosis of subjects with endoscopic evidence of severe disease (presence of ulceration)	60 - 75 min
Secondary	Area under the receiver operating characteristic curve of active disease	Area under the receiver operating characteristic curve, sensitivity and specificity of segmental [18F]FSPG PET/CT assessment for detecting bowel segments with endoscopic evidence of active disease	60 - 75 min